GB201800657D0 - A method for preparation of ibrutinib precursor - Google Patents

A method for preparation of ibrutinib precursor

Info

Publication number
GB201800657D0
GB201800657D0 GBGB1800657.7A GB201800657A GB201800657D0 GB 201800657 D0 GB201800657 D0 GB 201800657D0 GB 201800657 A GB201800657 A GB 201800657A GB 201800657 D0 GB201800657 D0 GB 201800657D0
Authority
GB
United Kingdom
Prior art keywords
ibrutinib
precursor
preparation
ibrutinib precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB1800657.7A
Other versions
GB2556535B (en
GB2556535A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB201800657D0 publication Critical patent/GB201800657D0/en
Publication of GB2556535A publication Critical patent/GB2556535A/en
Application granted granted Critical
Publication of GB2556535B publication Critical patent/GB2556535B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB1800657.7A 2015-08-31 2015-11-13 A method for preparation of ibrutinib precursor Active GB2556535B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-15-98A LV15201B (en) 2015-08-31 2015-08-31 The method for the preparation of ibrutinib intermediate
PCT/LV2015/000009 WO2017039425A1 (en) 2015-08-31 2015-11-13 A method for preparation of ibrutinib precursor

Publications (3)

Publication Number Publication Date
GB201800657D0 true GB201800657D0 (en) 2018-02-28
GB2556535A GB2556535A (en) 2018-05-30
GB2556535B GB2556535B (en) 2020-10-14

Family

ID=54754721

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1800657.7A Active GB2556535B (en) 2015-08-31 2015-11-13 A method for preparation of ibrutinib precursor

Country Status (4)

Country Link
CA (1) CA2987708C (en)
GB (1) GB2556535B (en)
LV (1) LV15201B (en)
WO (1) WO2017039425A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107674079B (en) * 2017-09-27 2019-12-13 黑龙江珍宝岛药业股份有限公司 Synthesis method of ibrutinib
CN113200986A (en) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 Preparation method of ibrutinib intermediate
CN114940678B (en) * 2021-09-26 2023-02-07 上海贵之言医药科技有限公司 Pyrazolopyrimidine ester compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080007621A1 (en) 2006-07-06 2008-01-10 Sbc Knowledge Ventures, Lp System and method of controlling access to an entrance
IL295053A (en) 2007-03-28 2022-09-01 Pharmacyclics Llc Inhibitors of brutons tyrosine kinase
AU2008323694A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
KR102311329B1 (en) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. Processes and intermediates for preparing a medicament

Also Published As

Publication number Publication date
WO2017039425A1 (en) 2017-03-09
CA2987708A1 (en) 2017-03-09
CA2987708C (en) 2022-08-02
GB2556535B (en) 2020-10-14
LV15201B (en) 2017-07-20
LV15201A (en) 2017-03-20
GB2556535A (en) 2018-05-30

Similar Documents

Publication Publication Date Title
HRP20201847T1 (en) Process for the preparation of a diarylthiohydantoin compound
HK1252627A1 (en) Method for providing a benefit to skin
HUE047041T2 (en) Method of producing a polyetheramine
IL281292B1 (en) Processes for the preparation of a diarylthiohydantoin compound
EP3116671C0 (en) Method of forming a compound roll
PL3295941T3 (en) Process for preparing form a of grapiprant
GB2556535B (en) A method for preparation of ibrutinib precursor
EP3221320A4 (en) A process for the preparation of ibrutinib
HK1208864A1 (en) A preparation method of ecteinascidin-743 intermediate -743
PL3041506T3 (en) A method of treatment
HUP1600128A2 (en) A new process for the preparation of elvitegravir
GB201407620D0 (en) Method of manufacture of a dispenser